BRIMONIDINE TARTRATE
| Brand name | MIRVASO |
|---|---|
| Active ingredient | BRIMONIDINE TARTRATE |
| Strength | EQ 0.33% BASE |
| Dosage form | GEL |
| Route | TOPICAL |
| Modality | Small molecule |
| FDA approval | August 2013 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8053427 | June 2031 | product |
| 8163725 | June 2031 | product |
| 10201517 | June 2031 | product |
| 9861632 | March 2031 | use U-1428 |
| 9861631 | March 2031 | use U-1428 |
| 8513247 | March 2031 | product |
| 8513249 | March 2031 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.